Catalytic Wealth RIA LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Catalytic Wealth RIA LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,269 shares of the biopharmaceutical company's stock, valued at approximately $1,334,000.

A number of other hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the period. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock valued at $868,757,000 after acquiring an additional 184,561 shares during the period. TD Asset Management Inc lifted its holdings in Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company's stock worth $259,402,000 after purchasing an additional 166,998 shares during the period. Finally, Swedbank AB acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $129,257,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.48% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Leerink Partners reiterated a "market perform" rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,107.25.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $2.95 during trading hours on Monday, reaching $825.47. 347,251 shares of the company were exchanged, compared to its average volume of 521,507. The firm has a market cap of $90.71 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 3.13 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $1,021.70 and a 200 day moving average of $1,038.20. Regeneron Pharmaceuticals, Inc. has a 12 month low of $784.96 and a 12 month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.